> Indeed, but even if 20% of people don't get their second shot on time
I think my worst case expectation is much worse than yours.
With a two week production shut down, I expect my corner of the world would not get new shipments for more than two weeks; higher priority places would be getting their previous orders filled before us, and we'd only get more once the backlog was filled. Also, I fully expect any production will take at least a week to be made public, so too late for an eager dosing regimine to start holding back.
Keep in mind, we're in winter, and winter storms often cause logistical problems.
The one dose efficacy data is too low confidence to make good decisions with. I'm open to the argument that it's better to use two doses to give two people one dose than to give one person two doses, but it would have been nice if that was trialed. There's also a related question of if you have a dose, if it's better to give that to a properly timed first dose recipient, or to give it to someone who hasn't received a dose yet. Again, there's not quality data; I would lean towards following the trial parameters.
> That's precisely where the government can step in and ensure that antibiotics therapies are available to workers in those facilities as well as daily tests.
Where has this suddenly competent government been for the past year? Yes, we expect a new executive in the US in a month, but the handoff takes time in normal conditions, and we have reason to believe this one will be more abrupt than many.
How do antibiotics help for covid?
How do daily tests help avert a shutdown when you can spread the disease while testing negative? One person could infect most of a shift of workers, given the right circumstances; more than one shift if they do handoff work to the next shift.
Supply chain workers for the vaccine aren't in the priority lists for the vaccine either. Anyway, covid isn't the only communicable disease possibility.